Determining Patterns In Trial Experiences of Recurrent Prostate Cancer Patients
Study Details
Study Description
Brief Summary
Clinical studies, with a dedicated focus on recurrent prostate cancer, play a pivotal role in evaluating the safety and effectiveness of novel treatments for this condition.
These trials serve as essential tools to determine whether new medications outperform traditional therapies, providing substantial evidence to endorse their broader utilization.
It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future patients with recurrent prostate cancer.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Outcome Measures
Primary Outcome Measures
- Number of patients who decide to participate in a recurrent prostate cancer clinical research [3 months]
- Rate of patients who remain in recurrent prostate cancer clinical research to trial completion [12 months]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patient is at least 18 years of age
-
Diagnosis of recurrent prostate cancer
-
Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
-
Enrolled in another research study
-
Patients with psychiatric illness/social situations that would limit compliance with study requirements
-
Inability to provide written informed consent
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Power Life Sciences | San Francisco | California | United States | 94107 |
Sponsors and Collaborators
- Power Life Sciences Inc.
Investigators
- Study Director: Michael B Gill, Power Life Sciences Inc.
Study Documents (Full-Text)
More Information
Publications
- Hefermehl LJ, Disteldorf D, Lehmann K. Acknowledging unreported problems with active surveillance for prostate cancer: a prospective single-centre observational study. BMJ Open. 2016 Feb 17;6(2):e010191. doi: 10.1136/bmjopen-2015-010191.
- Wollersheim BM, Helweg E, Tillier CN, van Muilekom HAM, de Blok W, van der Poel HG, van Asselt KM, Boekhout AH. The role of routine follow-up visits of prostate cancer survivors in addressing supportive care and information needs: a qualitative observational study. Support Care Cancer. 2021 Nov;29(11):6449-6457. doi: 10.1007/s00520-021-06222-9. Epub 2021 Apr 26.
- Ye D, Zhang W, Ma L, Du C, Xie L, Huang Y, Wei Q, Ye Z, Na Y. Adjuvant hormone therapy after radical prostatectomy in high-risk localized and locally advanced prostate cancer: First multicenter, observational study in China. Chin J Cancer Res. 2019 Jun;31(3):511-520. doi: 10.21147/j.issn.1000-9604.2019.03.13.
- 72630763